Literature DB >> 14708620

Mutations of the BRAF gene in benign and malignant melanocytic lesions.

Amir S Yazdi1, Gabriele Palmedo, Michael J Flaig, Ursula Puchta, Andrea Reckwerth, Arno Rütten, Thomas Mentzel, Heino Hügel, Markus Hantschke, Monika-Hildegard Schmid-Wendtner, Heinz Kutzner, Christian A Sander.   

Abstract

A single-point mutation in exon 15 of the BRAF gene has recently been reported in a high percentage in cultured melanoma cells and in 6 of 9 primary melanomas examined. To evaluate the impact of the T1796A BRAF mutation, we screened primary melanomas, various types of nevi and lesions where a melanoma developed in an underlying nevus. We could detect the mutation in 28 of 97 (29%) melanomas and in 39 of 187 (21%) nevi, including blue nevi (0/20) and Spitz nevi (0/69), which did not carry the mutation. In melanomas with an underlying nevus, either the mutation was present in both the laser-microdissected nevus cells and the laser-microdissected melanoma cells (3/14) or both lesions were negative for the BRAF mutation except one case. In conclusion, mutations in exon 15 of the BRAF gene are nonspecific for progression of a nevus to a melanoma. Other so far unknown cofactors seem to be of importance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14708620     DOI: 10.1046/j.1523-1747.2003.12559.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  44 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway.

Authors:  Janet L Maldonado; Luika Timmerman; Jane Fridlyand; Boris C Bastian
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 3.  [The role of molecular genetics in dermatologic diagnosis].

Authors:  M Braun-Falco; T Ruzicka
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

4.  Molecular alterations in malignant blue nevi and related blue lesions.

Authors:  Ismail Yilmaz; Mehmet Gamsizkan; Sule Ozturk Sari; Banu Yaman; Cuyan Demirkesen; Aylin Heper; Aylin Orgen Calli; Gizem Narli; Zafer Kucukodaci; Ufuk Berber; Dilaver Demirel; Taner Akalin; Murat Demiriz; Nesimi Buyukbabani
Journal:  Virchows Arch       Date:  2015-09-24       Impact factor: 4.064

Review 5.  Growth factors and oncogenes as targets in melanoma: lost in translation?

Authors:  Lawrence Kwong; Lynda Chin; Stephan N Wagner
Journal:  Adv Dermatol       Date:  2007

6.  Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.

Authors:  Shile Liang; Arati Sharma; Hsin-Hsin Peng; Gavin Robertson; Cheng Dong
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

7.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

Review 8.  Melanoma in pediatric, adolescent, and young adult patients.

Authors:  John M Kirkwood; Drazen M Jukic; Bruce J Averbook; Leonard S Sender
Journal:  Semin Oncol       Date:  2009-10       Impact factor: 4.929

9.  Molecular markers of tumor progression in melanoma.

Authors:  Joshua Rother; Dan Jones
Journal:  Curr Genomics       Date:  2009-06       Impact factor: 2.236

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.